GPCRs as potential therapeutic targets in preeclampsia.
GPCRs as potential therapeutic targets in preeclampsia.
复制标题
DOI：
10.1016/j.ddmod.2012.05.001
复制
发表时间：
2012
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
先兆子痫是一种重要的产科并发症，5%的女性在妊娠20周后出现，目前尚无特效治疗方法，也无法治愈。尽管该领域最近的大部分研究都集中在血管生成膜受体酪氨酸激酶 Flt1 和转化生长因子 β 辅助受体 Endoglin 的可溶形式上，但几个 GPCR 靶点及其激动剂或拮抗剂在先兆子痫中具有显着的临床潜力。在这篇综述中，我们讨论了该类别中几个最有前途的候选药物，包括降钙素受体样受体/受体活性修饰蛋白 1 复合物、血管紧张素 AT1、2 和 Mas 受体以及松弛素受体 RXFP1。我们还解决了围绕这些 GPCR 及其（拮抗）激动剂在先兆子痫中的作用和治疗潜力的一些争议。
Preeclampsia is an important obstetric complication that arises in 5% of women after the 20th week of gestation, for which there is no specific therapy and no cure. Although much of the recent investigation in this field has focused on soluble forms of the angiogenic membrane receptor tyrosine kinase Flt1 and the transforming growth factor β co-receptor Endoglin, there is significant clinical potential for several GPCR targets and their agonists or antagonists in preeclampsia. In this review, we discuss several of the most promising candidates in this category, including calcitonin receptor-like receptor / receptor activity modifying protein 1 complexes, the angiotensin AT1, 2 and Mas receptors, and the relaxin receptor RXFP1. We also address some of the controversies surrounding the roles and therapeutic potential of these GPCRs and their (ant)agonists in preeclampsia.